Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms, Squamous Cell 1Melanoma 1Lymphoma 1Liver Neoplasms 1Hodgkin Disease 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

pembrolizumab 5Cyclophosphamide 4Carboplatin 4Filgrastim 3fludarabine 2Thiotepa 2Temozolomide 2Riluzole 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Immunohistochemistry 2Drug Therapy 2Counseling 2Bupropion 2vofatamab 1utomilumab 1trastuzumab deruxtecan 1toripalimab 1tasquinimod 1sodium thiosulfate 1sargramostim 1saracatinib 1poly ICLC 1pertuzumab 1liposomal doxorubicin 1lenvatinib 1ixabepilone 1etoposide phosphate 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × advexin × Gynecologic × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡